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' Summary: The new photometric assay described by Fickenscher et al. (Thromb. Haemostas. 65 (1991) 535-540)
j for the determination of factor XIII facilitates the diagnosis of factor XIII deficiency. In spite of easy handling, this
| test should be used critically. Patients with hyperfibrinogenaemia showed factor XIII activities of less than 20%,
i whereas with an optimized assay we found normal factor XIII values. Also, the use of a fixed period of incubation
for the analysis is questionable, because the period of constant reaction rate occurs earlier and is shorter with high
factor XIII activities and later and longer with low factor XIII activities. A linear relation between factor XIII
activity and signal only exists up to 80% of activity.
In some plasma samples from patients with hyperfibrinogenaemia the factor XIII determination actually shows
decreased values for factor ΧΙΠ. During the reaction, a fibrin clot is formed. The resulting turbidity simulates an
increase in absorbance so that NADH consumption is apparently decreased. In six patients with hyperfibrinogen-
aemia (8.1—9.4 g/l), a factor XIII activity of 26 U/l or less was determined. Using 50 μΐ instead of 100 μΐ sample
volume, 50% (3/6) of the patients showed a normal factor XIII activity (80-96 U/l), whereas 50% (3/6) values of
6—15 U/l were found. In our modified assay we measured normal factor XIII activities (72—151 U/l) in all 6
patients. The procedure is optimized by reducing the sample voluine from 100 μΐ to 50 μΐ. The concentration of the
fibrin aggregation inhibitor is raised from 0.5 g/l to 1.0 g/l in the test solution, and the period of constant reaction
rate is used for the determination. Enzyme activity is expressed in U/l (37 °C). Optimized in this way, the assay
shows a linear relationship between the decrease of absorbance and factor XIII activity up to more than 128 U/l,
corresponding to 140%. Plasma samples with high concentrations of fibrinogen can be analysed without problems.
Precision was 2.3% in series and 2.8% from day to day, using a control plasma with 81 U/l; for a control plasma
with 35 U/l, the respective values were 4.9% and 5.8%. In apparently healthy 100 pefsons a reference interval of
factor XIII activity was established from 66 to 142 U/l or 73 to 155%.
Introduction turbidity of the reaction mixture results in falsely low
r, ,. t, r. t j 4 * * · r i * · factor XIII activities. These methods Start with the pre-Earher methods for the determination of coagulation . . . r
faetor XIII activity in plasma were time consuming, c!Pltatlon of flbnn°8en from ώβ samPle> f°r examPle
gave only semiquaatitative results, pr they involved usin8 bentomte as a P«*ipitatmg agent. As factor XIII
many processing Steps, often with a pretreatment of the is bound to fibrinogen, and the thrombin-mediated acti-
sample (l -4). Continuous photometric tests for the de- vati°n of factor xm is enhanced in- the presence of fi-
termination of factor XIII in pJasma have already been brinogen, the precipitation of this protein can lead to
described. In these assays, the clotting of the fibrin, decreased factor XIII values (5-10). A new photometric
formed by proteolysis of fibrinogen in the sample by test for the determination of factor XIII activity was
thrombin, has to be inhibited. Otherwise, .the increasing therefore recently described, in which fibrinogen is not
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precipitated, but a fibrin aggregation inhibitor (gly-pro-
arg-pro-ala-amide) is added to the System (11).
We have analysed the performance of this assay. The
test was optimized to analyse samples from patients with





= to refer to μraol
= average absorbance change (decrease) per rhinute
= catalytic concentration
The average frorn at least 4 absorbance differences and the factor
1746 were used to calculate factor XIII activity in U/l (37 °C).
Factor XIII activity (%) was estimated by using a linear Standard
plasma calibration curve (for more details see under results).
Materials and Methods
Plasma samples
Blood specimens were obtained by venipuncture in 0.129 mol/l
sodium citrate solution pH 6.05 (l part of sodium citrate and 9
parts of blood). After centrifugation for 15 minutes at 2000g and
room temperature, citrate plasma was separated. Samples were
stored at -20 °C for not longer than 4 weeks.
Reagents
Berichrom Factor XIII assay (lot: 24710; Behringwerke); Bovine
fibrinogen FXIII-free (lot: 43; Behringwerke); pure FXIII from
human plasma (lot: 089791; Calbiochem); fibrin aggregation in-
hibitor gly-pro-arg-pro-ala-amide, 86% (lot: 64HSO4; Behring-
werke); CTS Standard plasma (lot: 511513A; Behringwerke); CTS
control plasma N (lot: 511612A; Behringwerke); CTS control
plasma P (lot: 512612A; Behringwerke); sodium Chloride solution,
154 mmol/1 in double distilled water.
Instrumentation
Spectrophotometer Lambda 5 (Perkin-Elmer) fully mechanised
with cuvette exchange Station which can be temperature controlled
at 37 ± 0.2 °C (water bath) and plotter.
Statistical analysis
The Kolmogoroff-Smirnow-fittmg test and Lilliefors limits were
used to examine whether the reference values are normally distrib-
uted(12-14).
Methods
Assay according to Fickenscher
The reaction mixture was reconstituted in double distilled water
according to the manufacturer's instructions and incubated in l ml-
aliquots in reaction tubes at 37 °C (water bath). After addition of
100 μΐ sample and mixing in the reaction tube the measurement
was carried out in semimicro cuvettes prewarmed to 37 °C. Ab-
sorbance differences per minute (ΔΛ/min) were monitored continu-
ously over a period of up to 40 minutes. In this time the period
of constant reaction rate was determined in which the change of
absorbance per minute did not differ by more than 0.005/min. The
catalytic concentration was calculated according to LamberuBeer-
Bouguer's law (15):
b [U/l] = Δ/4/min 1.1 -10-






10^3 = total volume in cuvette, in litres
l O"3 = volume of sample, in litres
= light path of the cuvette, in m
= absorption coefficient of NADH at 340 nm, in m2/
mol
Optimized assay
The NAD reagent was dissolved in a solution containing l g/l fi-
brin aggregation inhibitor in distilled water. Activator reagent (con-
taining 5 mg liophilised fibrin aggregation inhibitor) was reconsti-
tuted with 5 ml of the dissolved NADH reagent to give 2 g/l fibrin
aggf egation inhibitor. The detection reagent was rec nstituted with
double distilled water and mixed with an equal volume of the rer
constituted activator reagent tp give the reaction mixture containing
l g/l fibrin aggregation inhibitor. Determination of factor ΧΙΠ ac-
tivity was perforrned s described above. For the reduced sample
volume of 50 μΐ the catalytic concentration is obtained s follows:
b [U/I] =
1.05-10,-3
630-10^3-0.01 0.05 · 10^:
= M/min · 3333
Results
As described in the literature (10, 11), during the first 3
minutes after the Start of the reaction the registration
curve shows a decrease of absorbance due to the conver-
sion of endogenous ammoriia (fig. 1). In plasma samples
with normal fibrinogen concentrations, a continuous de-
crease of the absorbance was observed. The lower the
factor XIII activity, the longer the linear period of the
reaction (up to 15 to 20 minutes); but with low factor
ΧΠί activity, the linear reaction period Starts later (fig.
2). Samples from patients with hyperfibrinogenaemia
form a clot in the cuvette during the measurement,
which makes the Interpretation of the results impos-
sible (fig. 3).
|
Fig. l Factor XIII assay according to Fickenscher. Reaction
course of a normal plasma pool from 10 persons. Fibrin aggrega-
tion mhibitor 0.5 g/l, 100 μΐ sample volume.
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Fig. 2 Factor XIII assay according to Fickenscher. Dependence
of the linear time course of factor XIII activity. 200% of factor
XIII was diluted with 154 mmol/1 NaCl solution to give 40, 80
and 120%. Another dilution step (l + l with 8 g/l factor Xlll-free










Fig. 3 Factor ΧΠΙ assay according to Fickenscher. Reaction
course of a patient plasrna with hyperfibrinogenaemia. Prothrorn-
bin ratio 1.05, thrombin time 15 s, activatedpfothrpmbin time 28 s,
fibrinogen concentratipn 8.5 g/l. Fibrin aggregation inhibitpr 0.5
g/l, 100 μΐ sample volume.
The assay was therefore modified by raising the concen-
tration of the fibrin aggregation inhibitor from 0.5 g/l to
1.0 g/l. This had no adverse effect in the determination
of a pool plasma ftoin 10 persons (flg. 4),· whereas in a
patient with hyperfibrinogenaernia the detection of fac-
tor XIII activity was improved. After 11 minutes, clot
formation simulates an increase of absorbance (flg. 5).
With 50% predilution of the patient sample (in
154 mmol/1 aqueous NaCl solution) the measured factor
XIII activity increased frorn 97 U/l in the non-optimized
to 133 U/l in the aptimized assay (flg. 3 and 5).
Examination of the dilution limit with the unmodified
reagent resulted in a linear measurement r nge up to
80% or 82 U/l (37 °C). The modified Version of the test
showed an equivalent value. Using 50 μΐ sample instead
of 100 .μΐ expands the r nge of linearity to 140%, corre-
sponding to 128 U/l (37 °C) (fig. 6). The calculation
factor changes to 3333.
In patients with hyperfibrinogenaernia, all samples
showed lower activities of factor XIII in the conven-
tional assay Using a 50% reduced sample volume, 50%
(3/6) of the patients seemed to have a decreased factor
XIII activity of less than 20%. Determination of factor
XIII activity with the twofold optimized assay showed
normal results in all patients (tab. 1).
The twofold optimized test variant was used to deter-
mine the precision data and to determine the reference
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Fig. 4 Factor XIII assay modified. Reaction course of a normal
plasrna pool from 10 persons. Fibrin aggregation inhibitor 1.0 g/l.
100 μΐ sample volume.
Fig. 5 Factor XIII assay modified. Reaction course of a patient
plasma with hyperfibrinogenaemia. Prothrombin ratio l .05, throm-
bin time 15 s, activated prothrombin time 18 s, fibrinogen 8.5 g/l.
Fibrin aggregation inhibitor 1.0 g/l, 100 μΐ sample volume.
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Fig. 6 Serial dilution of a Standard plasma (— X — fibrin aggrega-
tion Inhibitor 0.5 g/l [according to Fickenscher], 100 μΐ sample
volume; —o— fibrin aggregation inhibitor 1.0 g/l [modified assay],
100 μΐ sample volume; — ·— fibrin aggregation inhibitor 1.0 g/l,
50 μΐ sample* volume [optimized assay]).
Tab. l Factor XIII activities in patients with hyperfibrinogenae-
mia, using the unmodified assay according to Fickenscher with
























































agent containing 1.0 g/l fibrin aggregation inhibitor. The
appropriate period for calculating factor XIII activity
from the ΔΛ/min was determined (usually between 10
and 40 minutes) for each assay.
The precision was 2.3% in series and 2.8% from day
to day, for a control plasma with 81 U/l (37 °C). The
corresponding values for a control plasma with 35 U/l
(37 °C) were 4.9% and 5.8%, respectively. With 100 ap-
parently healthy persons, employees and students of the
university, between 19 and 44 years of age, the reference
interval ranged from 66 to 142 U/l (37 °C) or from 73
to 155%, and showed a normal distribution of the va-
lues (fig. 7).
Discussion
The continuous UV test for the determination of factor
XIII activity described by Fickenscher et al. (11) re-
presents a significant advance compared with earlier
methods. The results shown in, this paper demonstrate
that the method must be applied critically.
Using a fixed period of incubatiqn (5 to 10 minutes (11,
16, 17)) does not lead to correct values. The period of
constant reaction rate varies with different factor XIII
activities from 4 to 20 minutes. A variable assessment
of each single reaction course has t be iade (flg. 2).
Furthermore it is shown that the added amount of the
fibrin aggregation inhibitor is not s fficient to avoid clot
formation in reaction mixtures from patients with hyper-
fibrinogenaemia. Even a reduced sample volume of
50 μΐ, s reeommended by the manufacturer (reducing
the fibrinogen concentrations to the upper limit of the
reference interval) simulates a factor XIII deficiency of
15 U/l or less in 50% (3/6) of the patients (tab. 1). The
authors (11) describe a recovery of 96% factor XIII with
a fibrinogen concentration of 10.5 g/l. A possible expla-
nation of this findirig is that they added artificially puri-
fied fibrinogen to pooled plasma and did not analyse
samples from patients with hyperfibrinogenaemia. In
our study, the results are 2 to 3-fold higher, the time
required to attain a constant reaction rate is longer, and
the reaction curve was smoother using purified factor
XIII and purified fibrinogen than in a matrix of human
plasma (fig. 2) (10).
In the presence of a higher inhibitor concentration, the
Δ^/min values and the resulting measured values of the
50 65 80 95 11.0 125 140 155170[ /lj|
55 87 120 153 186[%]
Factor XIII activity
Fig. 7 Factor XIII assay optimized. Determination of the normal
r nge: 104 ± 38 U/l, 114 ±41% (χ ± 2 s) respectively. The refer-
ence values were normally distributed. Fibrin aggregation inhibitor
l .0 g/l; 50 μΐ sample volume.
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enzyme activity show a negligible decrease (fig. 6). This
is, however, compensated by determining the reference
interval under the same conditions. On the other band,
even in samples from patients with high fibrinogen con-
centrations, the recorded factor XIII activities are higher
than those found with the unmodified test (tab. 1).
Using the original method, we could not confirm the
linearity limit of 150% factor XIII activity described in
the literature. We found a value of 80%, corresponding
to 82 U/l. A possible explanation is that the other au-
thors analysed the change of absorbance between 5 and
10 minutes, while in the present study the period ofcon-
stant reaction rate up to at least 20 minutes was used
(11, 16, 17). For low factor XIII activities the 5 to 10
minute interval yields lower results, because the reaction
rate is still rising and the constant period is later.
,· Based on the data of this study a final modification of
the method was developed:
— The sample volume in the test is reduced from 100
to 50 .
- The concentration of the fibrin aggregation inhibitor
in the detection reagent is raised to 1.0 g/l.
This allows the analysis of samples with factor XIII ac-
tivities of more than 140% or 128 U/l (37 °C) and with
elevated fibrinogen concentrations with a reduced sensi-
tivity. The reference interval was also slightly higher
(73-155%) than in other studies (70-140% (11), 67-
147% (16), 60-133% (17)). An assay with an increased
concentration of fibrin aggregation inhibitor will in fti-
ture be available from the manufacturer.
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